DBV Technologies ADRs Rise After Up to $306.9M in New Financing

Dow Jones

Mar 28

By Chris Wack

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.

The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year.

Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern.

The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint.

The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

March 28, 2025 11:09 ET (15:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522198501"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522198501\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522198501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522198501","market":"us","top_or_hot":-1,"title":"DBV Technologies ADRs Rise After Up to $306.9M in New Financing","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. \n</p>\n<p>\n  The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year. \n</p>\n<p>\n  Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern. \n</p>\n<p>\n  The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint. \n</p>\n<p>\n  The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 28, 2025 11:09 ET (15:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies ADRs Rise After Up to $306.9M in New Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies ADRs Rise After Up to $306.9M in New Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-28 23:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. \n</p>\n<p>\n  The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year. \n</p>\n<p>\n  Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern. \n</p>\n<p>\n  The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint. \n</p>\n<p>\n  The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 28, 2025 11:09 ET (15:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DBVT","symbol_name":"DBV Technologies S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522198501","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522198501","pubTimestamp":1743174540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year.Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern.The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint.The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Applica","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DBVT":"DBV Technologies S.A.","DBV":"Invesco DB G10 Currency Harvest Fund","BK4139":"生物科技"},"translate_title":"DBV Technologies ADR在新融资高达3.069亿美元后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBV":1,"DBVT":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. \n\n\n  The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year. \n\n\n  Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern. \n\n\n  The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint. \n\n\n  The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 11:09 ET (15:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}